Literature DB >> 9546694

Castleman's disease and mesangial proliferative glomerulonephritis: the role of interleukin-6.

S L Lui1, K W Chan, F K Li, I K Cheng, T M Chan.   

Abstract

Renal complications of Castleman's disease (angiofollicular lymph node hyperplasia) are uncommon. The reported cases are very heterogeneous and their renal pathology ranged from minimal change disease, mesangial proliferative glomerulonephritis, to amyloidosis. We have previously reported two cases of Castleman's disease with renal complications. We now present two more such cases. In contrast to other reports, all our cases are of the plasma cell type and their renal pathology showed remarkable similarities, namely mesangial proliferation, interstitial plasma cell infiltration and negative immunofluorescence. The level of serum interleukin-6 (IL-6) in both patients was elevated at presentation and came down with immunosuppressive therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9546694     DOI: 10.1159/000044943

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  8 in total

Review 1.  Castleman's disease in childhood: report of three cases and review of the literature.

Authors:  Piero Farruggia; Antonino Trizzino; Nunzia Scibetta; Giovanni Cecchetto; Patrizia Guerrieri; Emanuele S G D'Amore; Paolo D'Angelo
Journal:  Ital J Pediatr       Date:  2011-10-20       Impact factor: 2.638

2.  Efficacy of tocilizumab, a humanized neutralizing antibody against interleukin-6 receptor, in progressive renal injury associated with Castleman's disease.

Authors:  Akito Maeshima; Masao Nakasatomi; Daizo Henmi; Shin Yamashita; Yoriaki Kaneko; Takashi Kuroiwa; Keiju Hiromura; Yoshihisa Nojima
Journal:  CEN Case Rep       Date:  2012-03-17

3.  Marked hepatomegaly due to AA type amyloidosis in a case with Castleman's disease.

Authors:  Noboru Yamagata; Jyunko Fujio; Risen Hirai; Mutsumi Matsumaru; Satoshi Tanimura; Chiho Inokuchi; Tateki Shikai; Naoki Takezako; Michiyo Nasu; Yoichi Sakata; Naohiro Sata; Hideo Nagai; Ken Saito; Akiyoshi Miwa
Journal:  Int J Hematol       Date:  2006-07       Impact factor: 2.490

Review 4.  An autopsy case of multicentric Castleman's disease associated with interstitial nephritis and secondary AA amyloidosis.

Authors:  Yuriko Morita-Hoshi; Shuji Tohda; Osamu Miura; Nobuo Nara
Journal:  Int J Hematol       Date:  2007-12-08       Impact factor: 2.490

Review 5.  Treatment of Castleman's disease.

Authors:  Angela Dispenzieri; Morie A Gertz
Journal:  Curr Treat Options Oncol       Date:  2005-05

6.  Multicentric Castleman disease of hyaline vascular variant presenting with unusual systemic manifestations: a case report.

Authors:  B M D B Basnayake; A W M Wazil; T Kannangara; N V I Ratnatunga; S Hewamana; A M Ameer
Journal:  J Med Case Rep       Date:  2017-05-14

7.  Interleukin-6 receptor inhibition with tocilizumab in various renal involvements associated with multicentric Castleman's disease: a report of three cases.

Authors:  Hirotaka Komaba; Takashi Nakazawa; Yutaka Yamaguchi; Shunichi Kumagai; Masafumi Fukagawa
Journal:  NDT Plus       Date:  2008-10-08

8.  Successful treatment with tocilizumab for refractory anemia and slowly progressive renal glomerulosclerosis in multicentric Castleman disease: A case report.

Authors:  Eri Sugawara; Taiki Sato; Yoshiharu Amasaki; Kazuaki Katsumata
Journal:  Medicine (Baltimore)       Date:  2022-02-25       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.